diaziquone has been researched along with Astrocytoma, Grade IV in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (83.33) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bedikian, AY; Benjamin, RS; Burgess, MA; Feun, LG; Fields, WS; Leavens, ME; Obbens, EA; Savaraj, N; Stewart, DJ; Yung, WK | 1 |
| Dowling, S; Gaspar, L; Halperin, EC; Herndon, J; Imperato, J; Salter, M | 1 |
| Al Sarraf, M; Austin, D; Decker, DA; Kresge, C; Wilner, HI | 1 |
| Bender, JF; Chaffee, B; Ensminger, WD; Gebarski, S; Greenberg, HS; Grillo-Lopez, AJ; Layton, PB; Meyer, M | 1 |
| Albright, RE; Bullard, DE; Burger, PC; Cairncross, JG; DeLong, ER; Friedman, HS; Khandekar, JD; Mahaley, MS; Schold, SC; Vick, NA | 1 |
| D'Incalci, M; Day, R; Erickson, LC; Kohn, KW; Kornblith, PL; Laurent, G; Sariban, E; Smith, BH; Zlotogorski, C | 1 |
1 trial(s) available for diaziquone and Astrocytoma, Grade IV
| Article | Year |
|---|---|
An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium.
Topics: Adult; Aged; Aged, 80 and over; Astrocytoma; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; Dose-Response Relationship, Radiation; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Oligodendroglioma; Radiography; Radiotherapy Dosage; Survival Analysis | 1993 |
5 other study(ies) available for diaziquone and Astrocytoma, Grade IV
| Article | Year |
|---|---|
A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Astrocytoma; Aziridines; Azirines; Benzoquinones; Bone Marrow Diseases; Brain Neoplasms; Drug Evaluation; Glioblastoma; Glioma; Humans; Middle Aged; Neoplasm Recurrence, Local | 1984 |
Phase II study of aziridinylbenzoquinone (AZQ: NSC-182986) in the treatment of malignant gliomas recurrent after radiation. Preliminary report.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Astrocytoma; Aziridines; Azirines; Benzoquinones; Brain Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Evaluation; Female; Follow-Up Studies; Glioblastoma; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma | 1985 |
Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas.
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Aziridines; Azirines; Benzoquinones; Bone Marrow; Brain Neoplasms; Carmustine; Drug Evaluation; Eye; Female; Glioblastoma; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Recurrence, Local | 1986 |
Phase II diaziquone-based chemotherapy trials in patients with anaplastic supratentorial astrocytic neoplasms.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Aziridines; Benzoquinones; Carmustine; Cerebellar Neoplasms; Child; Dacarbazine; Drug Evaluation; Glioblastoma; Humans; Middle Aged; Neoplasm Recurrence, Local; Statistics as Topic | 1987 |
DNA cross-linking responses of human malignant glioma cell strains to chloroethylnitrosoureas, cisplatin, and diaziquone.
Topics: Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Cells, Cultured; Cisplatin; Cross-Linking Reagents; DNA Damage; DNA, Neoplasm; Drug Resistance; Ethylnitrosourea; Glioblastoma; Humans; Neoplasm Proteins; Nitrosourea Compounds | 1987 |